Sientra Inc represents values of innovation, quality, and patient satisfaction. As a leading medical aesthetics company, Sientra is committed to providing cutting-edge solutions and exceptional experiences to its customers. With a focus on safety and efficacy, the company strives to deliver premium products for breast augmentation and body contouring procedures. Sientra's corporate philosophy revolves around empowering patients and surgeons alike by offering state-of-the-art technologies and comprehensive support. By prioritizing excellence, transparency, and patient-centricity, Sientra Inc aims to revolutionize the field of aesthetic medicine while ensuring the utmost satisfaction and confidence in its products and services.

Sientra Inc is primarily present in the United States.

Sientra Inc, a leading medical aesthetics company, has achieved several significant milestones. Firstly, the company received FDA approval for its breast implants, establishing its presence in the market. Additionally, Sientra launched its miraDry system, a revolutionary non-invasive treatment for excessive underarm sweating. The company also expanded its product portfolio by introducing various innovative solutions for breast reconstruction and augmentation, emphasizing their commitment to patient satisfaction. Furthermore, Sientra successfully completed clinical studies, further solidifying their reputation as a pioneer in the industry. With these notable achievements, Sientra Inc continues to enhance its position as a trusted provider of high-quality aesthetic products and services.

Sientra Inc is a renowned American medical aesthetics company, specializing in breast implants and other associated products. Founded in 2007, Sientra Inc has built a solid reputation for its innovative solutions and commitment to patient safety. The company is headquartered in Santa Barbara, California, and has evolved into a leader in the field of plastic surgery, serving both cosmetic and reconstructive surgeons. Sientra Inc prides itself on its advanced technology, high-quality products, and dedication to customer satisfaction. With a strong emphasis on research and development, Sientra Inc continues to make significant contributions to the aesthetics industry.

Some of the main competitors of Sientra Inc in the market include Allergan plc, Mentor Worldwide LLC, and Johnson & Johnson.

Sientra Inc is primarily active in the industries of medical devices, aesthetics, and plastic surgery.

The business model of Sientra Inc revolves around providing innovative and high-quality products and services in the medical aesthetics field. As a leading company in the industry, Sientra Inc specializes in developing, manufacturing, and marketing a wide range of products including breast implants, body contouring implants, and facial implants. Their comprehensive portfolio caters to both cosmetic and reconstructive plastic surgery markets, offering surgeons and patients with innovative solutions for enhancing and restoring aesthetics. Sientra Inc's commitment to research, development, and customer satisfaction has positioned them as a trusted and reliable partner for plastic surgeons and patients seeking safe and effective aesthetic solutions.

Sientra KGV ir -0,02.

Sientra KUV ir 0,01.

AlleAktien kvalitātes vērtējums Sientra ir 4/10.

gaidāmā Sientra apgrozījums ir 94,56 milj. USD.

gaidāmā Sientra peļņa ir -22,65 milj. USD.

Sientra Inc is a leading manufacturer and provider of innovative products for aesthetic surgery and reconstructive surgery. The company is headquartered in Santa Barbara, California and specializes in the development and distribution of high-quality breast implants, breast reconstruction products, and other aesthetic surgeries. The business model of Sientra is based on a combination of research, development, and marketing of products that meet the needs of patients and surgeons. The company offers a wide range of products as well as services to support and facilitate aesthetic surgeries. The production of breast implants, one of Sientra's main business areas, is a complex and highly specialized process. The company has a range of implants made from different materials, including silicone implants and breast implants in anatomical, round, and microtextured forms. Each implant is designed to have different sizes and shapes to meet the individual needs of patients. Another important business area of Sientra is breast reconstruction, which plays a significant role in restoring self-confidence and control over one's own life, especially for women who have undergone mastectomy due to breast cancer. Sientra offers a wide range of products to meet the needs of patients and surgeons. In addition to the production of breast implants and breast reconstruction products, the company also offers a wide range of services. This includes training and support for surgeons in using the products, as well as assistance for patients in making decisions about surgery and postoperative care. Sientra aims to provide excellent service and high-quality products to its customers. The company has a strong brand awareness and offers innovative, top-of-the-line products in a growing and demanding market that is constantly evolving. Sientra relies on a combination of research, development, marketing, and sales to meet the needs of all stakeholders. In summary, Sientra follows a successful business model based on a combination of high-quality products and services. The company offers its customers a wide range of products and services that are designed to meet the needs of patients and surgeons. Sientra is committed to expanding its market position and strengthening its brand awareness in order to remain a successful and leading provider of innovative aesthetic surgery.

Sientra izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Sientra vai uzņēmums nedod dividendes.

Sientra ISIN ir US82621J1051.

Sientra WKN ir A12EE3.

Sientra simbols ir SIEN.

Pēdējo 12 mēnešu laikā Sientra maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Sientra plāno maksāt dividendes 0 USD apmērā.

Sientra pašreizējā dividendu rentabilitāte ir .

Sientra maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Sientra pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Sientra tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Sientra apmērā 0 USD, kas tika izmaksāta 9.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 9.07.2024..

Pēdējās dividendes izmaksa notika 9.07.2024..

Gadā 2023, Sientra izmaksāja 0 USD dividendes.

Sientra dividendes tiek izmaksātas USD.